Evidence map›Paper›PMID 42736272›Full record

ArticleSignal transduction and targeted therapy2026

Interleukin-1 receptor-associated kinase 1 controls chemoresistance and immuno-killing in non-small cell lung cancer.

Sabrina Digiovanni, Claudia Giannotta, Luca Alessandri, Simona Fontana, Angelo Meoli, Paolo Bironzo, Alessandra Merlini, Gabriella Doronzo, Parab Sushant, Elisa Balmas and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Sabrina DigiovanniDepartment of Oncology, University of Torino, 10126, Torino, Italy. sabrina.digiovanni@unito.it.ORCID http://orcid.org/0009-0006-1815-3285
Claudia GiannottaMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.
Luca AlessandriMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.
Simona FontanaDepartment of Oncology, University of Torino, 10126, Torino, Italy.
Angelo MeoliDepartment of Oncology, University of Torino, 10126, Torino, Italy.
Paolo BironzoDepartment of Oncology, University of Torino, 10126, Torino, Italy.
Alessandra MerliniDepartment of Oncology, University of Torino, 10126, Torino, Italy.
Gabriella DoronzoTranslational Oncology Laboratory "Paola Gilardi", Department of Oncology at AOU San Luigi Hospital, University of Torino, 10043, Orbassano, Italy.
Parab SushantUniversity of Toulouse, CNRS, INSERM, CRCT, 31037, Toulouse, France.
Elisa BalmasMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.
Muhlis AkmanNeurooncology Laboratory, Faculty of Medicine, Bahcesehir University, 34353, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-9350-9652
Joanna KopeckaDepartment of Oncology, University of Torino, 10126, Torino, Italy.
Maddalena ArigoniMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.
Francesca NapoliPathology Unit, Department of Oncology at AOU San Luigi Hospital, 10043, Orbassano, Italy.
Julia WensDepartment of Drug Science and Technology, University of Torino, 10124, Torino, Italy.
Samuele TaralloDepartment of Drug Science and Technology, University of Torino, 10124, Torino, Italy.
Alessandro BerteroMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.ORCID http://orcid.org/0000-0002-4919-9087
Stefano GuglielmoDepartment of Drug Science and Technology, University of Torino, 10124, Torino, Italy.
Barbara RolandoDepartment of Drug Science and Technology, University of Torino, 10124, Torino, Italy.
Davide PalmaDepartment of Drug Science and Technology, University of Torino, 10124, Torino, Italy.
Luisella RighiPathology Unit, Department of Oncology at AOU San Luigi Hospital, 10043, Orbassano, Italy.
Massimo MassaiaMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.ORCID http://orcid.org/0000-0002-0021-1428
Raffaele CalogeroMolecular Biotechnology Center "Guido Tarone", University of Torino, 10126, Torino, Italy.
Federico BussolinoDepartment of Oncology, University of Torino, 10126, Torino, Italy.ORCID http://orcid.org/0000-0002-5348-1341
Silvia NovelloMedical Oncology Unit, Department of Oncology at AOU San Luigi Hospital, 10043, Orbassano, Italy.
Giorgio Vittorio ScagliottiMedical Oncology Unit, Department of Oncology at AOU San Luigi Hospital, 10043, Orbassano, Italy.
Iris Chiara Salaroglio *Department of Oncology, University of Torino, 10126, Torino, Italy.ORCID http://orcid.org/0000-0002-6043-3794
Chiara Riganti *Department of Oncology, University of Torino, 10126, Torino, Italy. chiara.riganti@unito.it.

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 21408Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 25950Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) MFAG 32164Fondazione Guido Berlucchi Mini-Grant KOPJ_RIC_COMP_24_01Fondazione Italiana per la Ricerca sul Cancro (Italian Foundation for Cancer Research) 22019Ministero della Salute (Ministry of Health, Italy) Ricerca Corrente 2025Regione Piemonte (Region of Piedmont) INFRA P
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) shows partial chemoimmunoresistance, driven by the upregulation of the drug efflux transporters ABCB1 and ABCC1 and the downregulation of the immunosensitizer protein ABCA1. To elucidate the molecular mechanisms underlying this chemoimmunoresistant phenotype, by performing a CRISPR-KO kinome screening, we identified interleukin-1 receptor-associated kinase 1 (IRAK1) as a key determinant of chemoimmunosensitive and chemoimmunoresistant phenotypes, defined as ABCB1/ABCC1

Indexed as

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmInterleukin-1 Receptor-Associated KinasesLung NeoplasmsAnimalsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter 1ATP Binding Cassette Transporter, Subfamily BCisplatinGene Expression Regulation, NeoplasticHumansMiceSignal TransductionABCA1 protein, humanABCB1 protein, humanATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter 1ATP Binding Cassette Transporter, Subfamily BCisplatinInterleukin-1 Receptor-Associated KinasesIRAK1 protein, humanmultidrug resistance-associated protein 1

Identifiers

PMID42736272
PMCPMC13575119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.